Tazverik™ (tazemetostat) – New indications
June 18, 2020 - Epizyme announced the FDA approval of Tazverik (tazemetostat), for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an enhancer of zeste homolog 2 (EZH2) mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and adult patients with R/R FL who have no satisfactory alternative treatment options.
Top